Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-08-2012 | Article

Clinical significance of enzymatic lysophosphatidylcholine (LPC) assay data in patients with sepsis

Authors: W. H. Cho, T. Park, Y. Y. Park, J. W. Huh, C.-M. Lim, Y. Koh, D.-K. Song, S.-B. Hong

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2012

Abstract

Lysophosphatidylcholine (LPC) has been suggested to serve as a useful prognostic marker for sepsis. However, existing LPC assays are complicated, time-consuming, and of limited application in real clinical situations. Thus, we investigated the serum LPC levels in sepsis patients using an enzymatic assay and analyzed the correlations between the serum LPC concentration and clinical characteristics. We prospectively collected blood samples from suspected sepsis patients, commencing on day 1 of sepsis. We analyzed all samples using an enzymatic assay. Additionally, we analyzed the serum LPC concentrations in a control group of 21 healthy blood donors. A total of 105 patients who fulfilled the sepsis criteria were included. The mean serum LPC concentration was 43.49 ± 33.09 μmol/L in sepsis patients, which was much lower than that of 21 healthy controls (234.68 ± 30.33 μmol/L, p < 0.001). Bacteremic sepsis was associated with a lower serum LPC concentration than non-bacteremic sepsis (34.81 ± 26.85 vs. 49.05 ± 35.63 μmol/L, p < 0.05). No difference in serum LPC concentration was evident between survivors and non-survivors. The serum LPC concentration tended to decrease with the severity of sepsis. The day 1 serum LPC concentration was decreased in patients with sepsis, especially when bacteremia was present. However, the serum LPC level did not correlate with disease severity and did not predict mortality from sepsis.

Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138–150PubMedCrossRef

Bulger EM, Maier RV (2000) Lipid mediators in the pathophysiology of critical illness. Crit Care Med 28(4 Suppl):N27–N36PubMedCrossRef

Quinn MT, Parthasarathy S, Steinberg D (1988) Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 85:2805–2809PubMedCrossRef

Nakano T, Raines EW, Abraham JA, Klagsbrun M, Ross R (1994) Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc Natl Acad Sci USA 91:1069–1073PubMedCrossRef

Liu-Wu Y, Hurt-Camejo E, Wiklund O (1998) Lysophosphatidylcholine induces the production of IL-1β by human monocytes. Atherosclerosis 137:351–357PubMedCrossRef

Coutant F, Perrin-Cocon L, Agaugué S, Delair T, André P, Lotteau V (2002) Mature dendritic cell generation promoted by lysophosphatidylcholine. J Immunol 169:1688–1695PubMed

Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M et al (1994) Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 269:31430–31435PubMed

Gómez-Muñoz A, O’Brien L, Hundal R, Steinbrecher UP (1999) Lysophosphatidylcholine stimulates phospholipase D activity in mouse peritoneal macrophages. J Lipid Res 40:988–993PubMed

De Vries HE, Ronken E, Reinders JH, Buchner B, Van Berkel TJ, Kuiper J (1998) Acute effects of oxidized low density lipoprotein on metabolic responses in macrophages. FASEB J 12:111–118PubMed

10.

Ngwenya BZ, Yamamoto N (1986) Effects of inflammation products on immune systems. Lysophosphatidylcholine stimulates macrophages. Cancer Immunol Immunother 21:174–182PubMedCrossRef

11.

Ramos MA, Kuzuya M, Esaki T, Miura S, Satake S, Asai T et al (1998) Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 18:1188–1196PubMedCrossRef

12.

McMurray HF, Parthasarathy S, Steinberg D (1993) Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest 92:1004–1008PubMedCrossRef

13.

Asaoka Y, Oka M, Yoshida K, Nishizuka Y (1991) Lysophosphatidylcholine as a possible second messenger synergistic to diacylglycerol and calcium ion for T-lymphocyte activation. Biochem Biophys Res Commun 178:1378–1385PubMedCrossRef

14.

Nishi E, Kume N, Ochi H, Moriwaki H, Wakatsuki Y, Higashiyama S et al (1997) Lysophosphatidylcholine increases expression of heparin-binding epidermal growth factor-like growth factor in human T lymphocytes. Circ Res 80:638–644PubMedCrossRef

15.

Nishi E, Kume N, Ueno Y, Ochi H, Moriwaki H, Kita T (1998) Lysophosphatidylcholine enhances cytokine-induced interferon gamma expression in human T lymphocytes. Circ Res 83:508–515PubMedCrossRef

16.

Asaoka Y, Oka M, Yoshida K, Sasaki Y, Nishizuka Y (1992) Role of lysophosphatidylcholine in T-lymphocyte activation: involvement of phospholipase A2 in signal transduction through protein kinase C. Proc Nat Acad Sci USA 89:6447–6451PubMedCrossRef

17.

Savage JE, Theron AJ, Anderson R (1993) Activation of neutrophil membrane-associated oxidative metabolism by ultraviolet radiation. J Invest Dermatol 101:532–536PubMedCrossRef

18.

Nishioka H, Horiuchi H, Arai H, Kita T (1998) Lysophosphatidylcholine generates superoxide anions through activation of phosphatidylinositol 3-kinase in human neutrophils. FEBS Lett 441:63–66PubMedCrossRef

19.

Kabarowski JH, Zhu K, Le LQ, Witte ON, Xu Y (2001) Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 293:702–705PubMedCrossRef

20.

Le LQ, Kabarowski JH, Weng Z, Satterthwaite AB, Harvill ET, Jensen ER et al (2001) Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity 14:561–571PubMedCrossRef

21.

Drobnik W, Liebisch G, Audebert FX, Frohlich D, Gluck T, Vogel P et al (2003) Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res 44:754–761PubMedCrossRef

22.

Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS et al (2004) Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 10:161–167PubMedCrossRef

23.

Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655PubMedCrossRef

24.

Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (1999) Manual of clinical microbiology, 7th edn. American Society for Microbiology, Washington, DC

25.

Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM (2011) Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol 135:182–189PubMedCrossRef

26.

Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA (2007) Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med 50:34–41PubMedCrossRef

27.

Sierra R, Rello J, Bailén MA, Benítez E, Gordillo A, León C et al (2004) C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome. Intensive Care Med 30:2038–2045PubMedCrossRef

Title: Clinical significance of enzymatic lysophosphatidylcholine (LPC) assay data in patients with sepsis
Authors: W. H. Cho
T. Park
Y. Y. Park
J. W. Huh
C.-M. Lim
Y. Koh
D.-K. Song
S.-B. Hong
Publication date: 01-08-2012
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2012
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-011-1505-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2012

Q fever across the Dutch border in Limburg province, Belgium

Aerosolized amikacin in patients with difficult-to-treat pulmonary nontuberculous mycobacteriosis

Rapid confirmation of suspected methicillin-resistant Staphylococcus aureus colonies on chromogenic agars by a new commercial PCR assay, the GenomEra MRSA/SA Diagnose

Serum capacity to neutralize superantigens does not affect the outcome of Staphylococcus aureus bacteremia

Rifampicin–miconazole-impregnated catheters save cost in jugular venous sites with tracheostomy

In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials